Search

everythinglearnresearchcommunity

for

Search:↓

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.

The new method found new shared genetic areas linked to both Type 2 Diabetes and Prostate Cancer.

Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Early baldness in men may indicate a higher risk of prostate cancer.

Early-onset male baldness may indicate a higher risk of prostate cancer.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Long-term diabetes is linked to lower prostate cancer risk.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.